BR100 Increased By (2.72%)
BR30 Increased By (3.56%)
KSE100 Increased By (2.44%)
KSE30 Increased By (2.48%)
AGHA 6.13 Increased By ▲ 0.10 (1.66%)
BECO 4.17 Increased By ▲ 0.31 (8.03%)
BML 62.00 Increased By ▲ 1.00 (1.64%)
BOP 30.90 Increased By ▲ 2.81 (10%)
CNERGY 12.03 Increased By ▲ 0.29 (2.47%)
CSIL 5.43 Increased By ▲ 0.13 (2.45%)
FCCL 56.80 Increased By ▲ 2.34 (4.3%)
FFL 13.32 Increased By ▲ 0.25 (1.91%)
FNEL 1.15 Increased By ▲ 0.04 (3.6%)
KEL 5.99 Increased By ▲ 0.36 (6.39%)
KOSM 5.48 Increased By ▲ 0.14 (2.62%)
LOTCHEM 24.36 Increased By ▲ 0.53 (2.22%)
MLCF 97.68 Increased By ▲ 4.70 (5.05%)
NBP 173.95 Increased By ▲ 10.75 (6.59%)
NCPL 48.48 Increased By ▲ 0.21 (0.44%)
NPL 50.27 Increased By ▲ 0.56 (1.13%)
OGDC 310.78 Increased By ▲ 7.15 (2.35%)
PACE 9.09 Increased By ▲ 0.12 (1.34%)
PAEL 33.10 Increased By ▲ 1.19 (3.73%)
PIBTL 13.18 Increased By ▲ 0.44 (3.45%)
PPL 217.20 Increased By ▲ 4.29 (2.01%)
PRL 85.60 Increased By ▲ 1.26 (1.49%)
PTC 46.30 Increased By ▲ 1.31 (2.91%)
SSGC 23.30 Increased By ▲ 0.47 (2.06%)
TBL 9.00 Increased By ▲ 0.12 (1.35%)
TELE 6.73 Increased By ▲ 0.23 (3.54%)
TPL 25.99 Increased By ▲ 1.73 (7.13%)
TPLP 12.71 Increased By ▲ 0.72 (6.01%)
TREET 23.86 Increased By ▲ 0.72 (3.11%)
TRG 53.09 Increased By ▲ 1.62 (3.15%)
World

EU states report offers for 900 million vaccine by ‘alleged intermediaries’ - anti-fraud body

  • OLAF has opened an inquiry earlier this month into scam vaccine offers as the bloc faces increasing risk of fraud in that area.
  • Pharmaceutical companies have said they only sell directly to governments.
Published Updated
By

BRUSSELS: Several European Union countries reported offers from "alleged intermediaries" for 900 million doses of COVID vaccines at a total asking price of some 12.7 billion euros, the bloc's anti-fraud agency OLAF said on Thursday.

OLAF has opened an inquiry earlier this month into scam vaccine offers as the bloc faces increasing risk of fraud in that area.

Pharmaceutical companies have said they only sell directly to governments.

Comments

Comments are closed for this article.